AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16050407
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of RAS blockers in presence of microalbuminuria
Trial: 12853792
Drug: 180 mmol
RxNorm normalized name: PEG-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mmol (3%) ALA administered for 6 hours
Trial: 12853792
Drug: 8 mmol
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mmol (0.2%) HAL administered for 4 hours
Trial: 12853792
Drug: 8 mmol
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept)
Trial: 12853792
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of HAL
Trial: 12853792
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of ALA or HAL
Trial: 2696390
Drug: Classical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical therapy consisting of isoniazid and rifampicin for a nine-month period.
Trial: 29722425
Drug: Indocyanine green-based
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green-based photodynamic therapy
Trial: 29722425
Drug: Indocyanine green-based
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green-based photodynamic therapy with 805-nm diode laser
Trial: 29722425
Drug: Indocyanine green-based
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green-based photodynamic therapy with 830-nm light-emitting diode
Trial: 29722425
Drug: Methyl aminolevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate-based photodynamic therapy
Trial: 18566974
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses of KW-6002 greater than 5 mg
Trial: 18566974
Drug: MRS 1745
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRS 1745 (A(2B) receptor selective antagonist)
Trial: 16227335
Drug: i.m. tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. tramadol 100 mg
Trial: 11862087
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 100 mg orally, three times daily
Trial: 11862087
Drug: Topical steroid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid, topical antibiotic, and artificial tears
Trial: 10549464
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: propofol 2 mg kg‐1 and remifentanil 2 micrograms kg‐1
Trial: 10549464
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: propofol 2 mg kg‐1, remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Trial: 7606988
Drug: Salmeterol, 50
RxNorm normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 50 micrograms twice a day
Trial: 7606988
Drug: Albuterol, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol, 400 micrograms four times a day
Trial: 31234865
Drug: Single low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single low-dose primaquine added to artemether-lumefantrine treatment
Trial: 31234865
Drug: Artemether-lumefantrine treatment
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine treatment without primaquine
Trial: 28070970
Drug: Baby lotion
RxNorm normalized name: Baby Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baby lotion (L)
Trial: 23126384
Drug: montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: montelukast (5 or 10 mg, once daily)
Trial: 23126384
Drug: salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol (50 μg, b.i.d.)
Trial: 16426100
Drug: Modafinil (340
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (340 mg, N = 44; 425 mg, N = 82)
Trial: 14503435
Drug: Constraint-Induced Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Therapy (CI therapy)
Trial: 8724448
Drug: Scopolamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.1 mg, 0.25 mg, 0.5 mg)
Trial: 1314536
Drug: Live-attenuated vaccine
RxNorm normalized name: Chikungunya vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated vaccine (28,000 pfu, 2800 pfu, or 280 pfu of Oka/Merck strain virus)
Trial: 1314536
Drug: Heat-inactivated vaccine
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated vaccine (comparable antigen content to live vaccine)
Trial: 1314536
Drug: High-dose groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose groups (greater than or equal to 7.1 antigen units)
Trial: 1314536
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose (less than or equal to 0.71 antigen units)
Trial: 2864890
Drug: Procaterol hydrochloride
RxNorm normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol hydrochloride tablet formulation
Trial: 2864890
Drug: Procaterol hydrochloride
RxNorm normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol hydrochloride syrup formulation
Trial: 26311100
Drug: Intra-articular dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular dexmedetomidine (2 μg/kg body weight) and ropivacaine (18 mL)
Trial: 26311100
Drug: Intra-articular dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular dexmedetomidine (1 μg/kg body weight) and ropivacaine (18 mL)
Trial: 26311100
Drug: Intra-articular ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular ropivacaine (20 mL)
Trial: 23567483
Drug: 0.1 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 μg/kg/min remifentanil infusion (Group R1)
Trial: 23567483
Drug: 0.2 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/kg/min remifentanil infusion (Group R2)
Trial: 18454862
Drug: Walnut supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut supplement (75 g/d)
Trial: 16567267
Drug: High-dose thiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thiamine (250 mg/day) and pyridoxine (200 mg/day)
Trial: 3189208
Drug: Vitamin-mineral supplements
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-mineral supplements
Trial: 31664766
Drug: BOS161721 (1-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOS161721 (1-240 mg, intravenous and subcutaneous doses)
Trial: 31664766
Drug: BOS161721 (subcutaneous)
RxNorm normalized name: Immunoglobulin g1 (251-tyrosine,253-threonine,255-glutamic acid), anti-(human interleukin 21) (human-mus musculus monoclonal bos161721 .gamma.1-chain), disulfide with human-mus musculus monoclonal bos161721 .kappa.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOS161721 (subcutaneous)
Trial: 16970214
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/d) added to ongoing statin therapy for 6 weeks
Trial: 16970214
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to ongoing statin therapy for 6 weeks
Trial: 11385384
Drug: Acetylcholine (10(‐8),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (10(‐8), 10(‐7), 10(‐6), and 10(‐5) mol/L)
Trial: 30094437
Drug: Oat protein
RxNorm normalized name: Potassium Olivoyl Hydrolyzed Oat Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat protein (25 g protein) for 19 days
Trial: 24920942
Drug: Coload (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coload (15 ml/kg of crystalloid after intrathecal injection)
Trial: 24920942
Drug: Preload (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preload (15 ml/kg of crystalloid before intrathecal injection)
Trial: 22419728
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg iv zoledronate
Trial: 14517524
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (0.35 mg/kg/d) and/or prednisolone (2 mg/kg/day)
Trial: 9504181
Drug: NaF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF treatment (0.02%, 0.05% or 0.1%)
Trial: 2878675
Drug: Nifedipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (in patients pretreated with a beta blocker)
Trial: 31698917
Drug: Adipose-derived stromal
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived stromal cell (ASC) therapy
Trial: 28453471
Drug: ELND005 (scyllo-Inositol)
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ELND005 (scyllo-Inositol) 250 mg twice daily (BID)
Trial: 28453471
Drug: ELND005 (scyllo-Inositol)
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ELND005 (scyllo-Inositol) 250 mg once daily (QD)
Trial: 21045172
Drug: Whey (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey (0.3 g/kg lean body mass)
Trial: 21045172
Drug: Casein (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (0.3 g/kg lean body mass)
Trial: 19681415
Drug: Ketamine pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine pre-treatment (10 mg in 1.0 ml saline) under tourniquet for 30 seconds before propofol injection.
Trial: 19681415
Drug: Ketamine added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine added to propofol (10 mg in 9 ml propofol mixed with 1.0 ml saline).
Trial: 16696744
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 mug daily self-injection for a median of 19 months, with daily oral supplements of 1,000 mg calcium and 400 to 1,200 IU vitamin D.
Trial: 9777817
Drug: Incorrect treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect treatment for renin profile but correct for age-race subgroup
Trial: 7889894
Drug: K‐85 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K‐85 2 g twice daily
Trial: 7889894
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil 2 g twice daily (placebo)
Trial: 30453950
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri V3401 (5 × 10^9 CFU daily)
Trial: 28157261
Drug: MG-assisted TSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG-assisted TSP
Trial: 21273603
Drug: CCND1 rs9344
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCND1 rs9344 genotype (G allele carriers: GG or AG)
Trial: 16968574
Drug: Trazodone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone prolonged-release 150-450 mg/day (n = 62)
Trial: 16968574
Drug: Sertraline 50-100
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50-100 mg/day (n = 60)
Trial: 15351368
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEP and SEP
Trial: 11049800
Drug: Oral miltefosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral miltefosine, 50 mg given twice daily for 14 days (group A)
Trial: 11049800
Drug: Oral miltefosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral miltefosine, 50 mg given twice daily for 21 days (group B)
Trial: 11049800
Drug: Oral miltefosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral miltefosine, 50 mg given twice daily for 28 days (group C)
Trial: 7618720
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of bupivacaine
Trial: 7618720
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of bupivacaine plus 10 micrograms of sufentanil
Trial: 7618720
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of bupivacaine and 10 micrograms of sufentanil
Trial: 2144206
Drug: Zoladex depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex depot supplemented by flutamide 250 mg 3 qid
Trial: 318577
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid
Trial: 22038523
Drug: Rosiglitazone 4‐8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4‐8 mg/day
Trial: 22038523
Drug: Pioglitazone 30‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30‐45 mg/day
Trial: 20308972
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of arginine ingested in a single dose 60 minutes prior to exercise
Trial: 16291760
Drug: Synthetic protein
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic protein N (10, 30, or 100 microg/dose)
Trial: 16291760
Drug: Synthetic protein
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic protein R (10, 30, or 100 microg/dose)
Trial: 16291760
Drug: Synthetic protein
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic protein C (10, 30, or 100 microg/dose)
Trial: 9479340
Drug: CytoRich liquid-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CytoRich liquid-based preparation (AutoCyte, Inc.)
Trial: 8558939
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg/m2 orally)
Trial: 8558939
Drug: Allopurinol (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (one dose)
Trial: 8558939
Drug: Allopurinol (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (concomitant with methotrexate therapy)
Trial: 8558939
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate therapy only
Trial: 6184574
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nitrendipine
Trial: 28877748
Drug: GSK2586881 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586881 (0.4 mg/kg) administered twice daily for 3 days
Trial: 17129383
Drug: Paclitaxel at
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel at a dose of 175, 210, or 250 mg/m2
Trial: 11401123
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg daily for 12 weeks
Trial: 6695162
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting beta blocker (oxprenolol R 160 mg)
Trial: 30807294
Drug: Modified dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dual therapy
Trial: 20190028
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2 x 600 mg/daily for 8 weeks
Trial: 15823451
Drug: Shortened version
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shortened version of the ACQ (symptoms plus short‐acting beta2‐agonist)
Trial: 12753323
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal using Simulect (IL-2 receptor inhibitor)
Trial: 10839763
Drug: Azithromycin 600
RxNorm normalized name: azithromycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 600 mg orally once a week for 1 year
Trial: 2860043
Drug: Steroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids or a combination with prednisolone and sulfasalazine
Trial: 29898870
Drug: Vaccine regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine regimen (intramuscular injection of ALVAC-HIV vector [vCP2438] at 0, 1, 3, 6, and 12 months plus bivalent subtype C gp120 and MF59 adjuvant at 3, 6, and 12 months)
Trial: 29898870
Drug: Vaccine regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine regimen
Trial: 17698218
Drug: tirofiban infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban infusion and sirolimus-eluting stents (SES)
Trial: 17698218
Drug: tirofiban infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban infusion and SES
Trial: 1451242
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (1.5 M units) administered over 30 minutes
Trial: 22527648
Drug: Repeated interventional
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated interventional treatment (average 10 times, approximately 107 single injections during each treatment cycle)
Trial: 20855664
Drug: Baseline GDF-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline GDF-15 levels (per 100 ng/L)
Trial: 18030865
Drug: Visual medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual medication schedule with brief counseling
Trial: 7588454
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) monotherapy
Trial: 28838862
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg per day)
Trial: 25452452
Drug: Nivolumab 2
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 2 mg/kg
Trial: 25452452
Drug: Nivolumab 10
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 10 mg/kg
Trial: 19119079
Drug: Routine hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hospital based 6‐monthly clinical review
Trial: 14587108
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis during laparoscopic cholecystectomy
Trial: 10877008
Drug: Effervescent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent paracetamol tablets (2 x 500 mg Pinex Brusetablett, Alpharma AS)
Trial: 10877008
Drug: Ordinary paracetamol
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary paracetamol tablets (2 x 500 mg Panodil tablets, SmithKline Beecham)
Trial: 10877008
Drug: Effervescent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent paracetamol tablets
Trial: 10877008
Drug: Ordinary paracetamol
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary paracetamol tablets
Trial: 9408153
Drug: Doxorubicin-containing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-containing chemotherapy with involved field radiotherapy (n = 58)
Trial: 9408153
Drug: Doxorubicin-containing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-containing chemotherapy without involved field radiotherapy (n = 18)
Trial: 8458821
Drug: Antioxidant vitamin
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamin mixture (daily doses of 592 mg of alpha‐tocopherol equivalents, 1,000 mg of ascorbic acid, and 30 mg of beta‐carotene)
Trial: 29444414
Drug: Caffeine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.8 ± 0.4 mg/kg body mass)
Trial: 23225450
Drug: Temsirolimus and
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus and bevacizumab combination (arm A)
Trial: 8198025
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg twice daily, starting 2 weeks before PTCA and continuing after successful PTCA until follow-up angiography at 26 +/- 2 weeks.
Trial: 10075142
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg twice daily
Trial: 3147048
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose theophylline (5-10 mg/l)